

Ref: EPL/CS/SE/0016/2024

Date: October 03, 2024

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Incorporation of Wholly-owned Subsidiary


We refer to our disclosure dated September 13, 2024 (copy attached), pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), related to proposed incorporation of wholly-owned subsidiary (WoS) by the name "Emcutix Biopharmaceuticals Limited" in Pune, Maharashtra, India.

Further to our above disclosure, we would like to inform that as per the approval of Registrar of Companies, a WoS named "Emcutix Biopharmaceuticals Limited" is incorporated on October 03, 2024. All the particulars mentioned in the disclosure dated September 13, 2024, remains the same.

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited



Chetan Sharma

Company Secretary & Compliance Officer

Membership Number: F8352

**Emcure Pharmaceuticals Limited**

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: U24231PN1981PLC024251

Ref: EPL/CS/SE/0013/2024

Date: September 13, 2024

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Intimation of proposed incorporation of a Wholly-owned Subsidiary


Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform that a Committee of the Board of Directors of the Company in their meeting held today i.e. September 13, 2024, has *inter-alia* approved the incorporation of a wholly-owned subsidiary by the name "Emcutix Biopharmaceuticals Limited" in Pune, Maharashtra, India.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the Listing Regulations are provided in **Annexure A**, enclosed herewith.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**



Chetan Sharma

Company Secretary & Compliance Officer



Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: U24231PN1981PLC024251

Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No	Particulars	Information
a)	Name of the target entity, details in brief such as size, turnover etc.	<p>Name: Emcutix Biopharmaceuticals Limited</p> <p>Proposed Authorized Share Capital: Rs. 10,00,00,000/- (Rupees Ten Crore only)</p> <p>Proposed Paid-up Share Capital: Rs. 1,00,000/- (Rupees One Lakh only)</p> <p>Turnover: Not Applicable, as the entity is yet to be incorporated.</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	<p>The proposed entity would be Wholly-owned Subsidiary (WoS) of the Company and hence once incorporated, the WoS will be a related party of the Company and other subsidiaries.</p> <p>Save and except what is mentioned above, the Promoters / Promoter Group / Group Companies are not interested in the transaction.</p>
c)	Industry to which the entity being acquired belongs	Pharmaceuticals
d)	Objects and impacts of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	WoS is being incorporated to manufacture, promote, sale and distribute pharmaceuticals and other related product(s).
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
f)	Indicative time period for completion of the acquisition	Not Applicable
g)	Nature of consideration - whether cash consideration or share swap and details of the same	100% subscription to initial paid-up share capital of Rs. 1,00,000/- (Rupees One Lakh only) is in cash.
h)	Cost of acquisition or the price at which the shares are acquired	At face value of Rs.10/- per share.

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 - 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** U24231PN1981PLC024251



Emcure

i)	Percentage of shareholding/ control acquired and/ or number of shares acquired	100% subscription to the share capital of the proposed WoS.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable since the proposed WoS is yet to be incorporated.



Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** U24231PN1981PLC024251